---
title: "EXOZ.US (EXOZ.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EXOZ.US/news.md"
symbol: "EXOZ.US"
name: "EXOZ.US"
parent: "https://longbridge.com/en/quote/EXOZ.US.md"
datetime: "2026-03-03T18:29:25.664Z"
locales:
  - [en](https://longbridge.com/en/quote/EXOZ.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EXOZ.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EXOZ.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/EXOZ.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/EXOZ.US/news.md)


# EXOZ.US (EXOZ.US) — Related News

### [Exosens surpasses 2025 targets with robust Defense sales, focusing on night vision and imaging. Revised mid-term goal: Faster profit growth.](https://longbridge.com/en/news/276569622.md)
*2026-02-23T06:16:31.000Z*
> Exosens has exceeded its 2025 targets, driven by strong sales in defense, particularly in night vision and imaging techn

### [eXoZymes Inc. Announces Strategic Shift to Focus on Pharmaceutical and Nutraceutical Markets, Prioritizing AI-Enhanced Enzyme Platform for High-Value Applications](https://longbridge.com/en/news/275512206.md)
*2026-02-10T21:20:25.000Z*
> Exozymes Inc. has announced a strategic shift to focus on the pharmaceutical and nutraceutical markets, utilizing its AI

### [Exousia Pro, Inc. speeds up growth with 3rd telehealth acquisition, paving way for cost-effective customer acquisition.](https://longbridge.com/en/news/275484374.md)
*2026-02-10T15:31:06.000Z*
> Exousia Pro, Inc. has accelerated its growth strategy by completing its third telehealth acquisition, which is expected 

### [Exozymes CEO Outlines Biosolutions Growth Strategy in Nasdaq Interview](https://longbridge.com/en/news/275036611.md)
*2026-02-05T21:52:58.000Z*
> Michael Heltzen, CEO of eXoZymes Inc. (Nasdaq: EXOZ), discussed the company's growth strategy in a Nasdaq interview. He 

### [Exozymes Inc. Reports 99.6% Purity and 90% Yield in 100-Liter NCT Pilot Production Run](https://longbridge.com/en/news/274959364.md)
*2026-02-05T11:04:37.000Z*
> eXoZymes Inc. has reported successful results from its 100-liter pilot production run of NCT, achieving 99% reaction con

### [eXoZymes (NASDAQ:EXOZ) Trading Up 5.5%  - Here's Why](https://longbridge.com/en/news/274775359.md)
*2026-02-04T07:53:28.000Z*
> eXoZymes (NASDAQ:EXOZ) saw its stock price increase by 5.5% to $11.25, despite a trading volume decline of 17% from the 

### [eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run](https://longbridge.com/en/news/274227407.md)
*2026-01-30T00:57:39.000Z*
> eXoZymes Inc. has reported successful results from its initial pilot production run of N-trans-caffeoyltyramine (NCT), a

### [Exozymes Reports Improved Enzyme Performance at Commercial Scale](https://longbridge.com/en/news/274225374.md)
*2026-01-30T00:38:10.000Z*
> Exozymes Inc. has reported improved performance of its AI-enhanced enzymes during a 100-liter pilot production run of NC